As a consequence, an inactivation of NF-κB and missing NF-κB-dependent production of tumor-promoting factors such as COX2, IDO, or interleukin 10 induction can provide new therapeutic opportunities and minimize negative side effects [28]. This evidence concerns the gene PTGS2 and neoplasm.